脓毒症危重患者早期血浆血管生成素-2对ARDS和死亡的预后价值
该研究在757例脓毒症患者(含267例ARDS)中检测急诊或ICU早期血浆Ang-2,采用多变量模型分析其与ARDS发生及30天死亡的关系。结果显示早期Ang-2升高与基线病情严重程度更高、ARDS发生及死亡风险相关;Ang-2与死亡的关联在脓毒症合并ARDS患者中强于单纯脓毒症患者(OR 1.81 vs 1.52每log Ang-2增加)。作者认为这些发现可能为患者风险预测模型提供信息,并强化Ang-2作为筛选靶向血管损伤新型治疗药物生物标志物的证据。
要点
- 757例脓毒症患者(含267例ARDS)中,早期血浆Ang-2升高与基线病情严重程度更高、ARDS发生及死亡风险相关。
- Ang-2与死亡的关联在脓毒症合并ARDS患者中强于单纯脓毒症患者:OR 1.81 vs 1.52(每log Ang-2增加)。
- Ang-2与ARDS发生独立相关,提示其可作为脓毒症相关肺损伤的早期预后标志物。
- 作者认为Ang-2可能作为筛选靶向血管损伤新型治疗药物的生物标志物。
适用人群与场景
- 脓毒症患者,在急诊科或ICU早期入组,入组时间在COVID-19大流行之前;共757例,其中267例合并ARDS。
研究设计与关键结果
- 研究类型为队列研究,纳入757例脓毒症患者(含267例ARDS),在急诊或ICU早期测量血浆Ang-2,采用多变量模型分析其与ARDS发生及30天死亡的关系。
- 早期血浆Ang-2升高与基线病情严重程度更高、ARDS发生及死亡风险相关。
- Ang-2与死亡的关联在脓毒症合并ARDS患者中强于单纯脓毒症患者:OR 1.81 vs 1.52(每log Ang-2增加)。
证据类型、等级与局限
- 证据类型:队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现可能为患者风险预测模型提供信息,并强化Ang-2作为筛选靶向血管损伤新型治疗药物的生物标志物的证据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Angiopoietin-2 (Ang-2) is associated with vascular endothelial injury and permeability in the acute respiratory distress syndrome (ARDS) and sepsis. Elevated circulating Ang-2 levels may identify critically ill patients with distinct pathobiology amenable to targeted therapy. We hypothesized that plasma Ang-2 measured shortly after hospitalization among patients with sepsis would be associated with the development of ARDS and poor clinical outcomes. To test this hypothesis, we measured plasma Ang-2 in a cohort of 757 patients with sepsis, including 267 with ARDS, enrolled in the emergency department or early in their ICU course before the COVID-19 pandemic. Multivariable models were used to test the association of Ang-2 with the development of ARDS and 30-day morality. We found that early plasma Ang-2 in sepsis was associated with higher baseline severity of illness, the development of ARDS, and mortality risk. The association between Ang-2 and mortality was strongest among patients with ARDS and sepsis as compared to those with sepsis alone (OR 1.81 vs. 1.52 per log Ang-2 increase). These findings might inform models testing patient risk prediction and strengthen the evidence for Ang-2 as an appealing biomarker for patient selection for novel therapeutic agents to target vascular injury in sepsis and ARDS.
参考来源
- Rosenberger CM, Wick KD, Zhuo H, et al. Early plasma angiopoietin-2 is prognostic for ARDS and mortality among critically ill patients with sepsis. Crit Care. 2023. PMID: 37312169. doi:10.1186/s13054-023-04525-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。